NASDAQ · Biotechnology

TPST (TPST) Stock

$0.93 +0.94% NASDAQ: TPST Healthcare

Valuation

MetricValue
Price$0.93
Market Cap$4.15M
P/E Ratio-0.29
P/B Ratio1.18
P/S Ratio0.00
EPS (TTM)$-6.33
52-Week High$12.23
52-Week Low$0.90
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-371.43%
ROA-152.94%
ROCE-385.71%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity9.55
Current Ratio2.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-27.0M$-35.0M$-29.0M$-42.0M$-27.0M
Net Profit$-28.0M$-36.0M$-29.0M$-42.0M$-26.0M
EPS$-7.80$-3.18$-1.91$-1.50$-6.33
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$73.0M$46.0M$52.0M$41.0M$17.0M
Total Liabilities$37.0M$28.0M$25.0M$22.0M$10.0M
Cash$52.0M$31.0M$39.0M$30.0M$8.0M
Borrowings$19.0M$22.0M$21.0M$15.0M$8.0M

Latest News

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T GlobeNewswire · Jul 21, 2026 Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 GlobeNewswire · Jul 15, 2026 Rani Therapeutics Names Nicholas Maestas CFO MT Newswires · Jun 29, 2026 Tempest Therapeutics Registers 2.43 Million Shares for Resale MT Newswires · Jun 26, 2026 Tempest Therapeutics CFO Nicholas Maestas Resigns MT Newswires · Jun 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-26.0M$-31.0M$-27.0M$-33.0M$-27.0M
Investing Cash Flow$0$-1.0M$0$-1.0M$0
Financing Cash Flow$11.0M$0$0$0$0
Net Cash Flow$33.0M$-20.0M$8.0M$-9.0M$-23.0M
Free Cash Flow$-26.0M$-32.0M$-28.0M$-33.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-319.39%
Quick Ratio0.74
Interest Coverage—
Return 1Y-84.01%
Return 3Y-92.93%
Return 5Y-99.58%

Ownership

Insiders Held31.78%
Institutions Held26.29%
Institutions Float Held38.53%
Institutional HolderSharesReport Date
Versant Venture Management, LLC269,7722026-03-31
Vanguard Capital Management LLC233,8882026-03-31
Geode Capital Management, LLC86,9902026-03-31
Vanguard Fiduciary Trust Co68,9082026-03-31
Blackrock Inc.39,0682026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%

About TPST

TPST is led by CEO Matthew Angel, employs 24 people, headquartered in US, publicly traded since 2012.

TPST stock trades at $0.93 with a market capitalization of $4.15M. The stock is valued at a price-to-earnings (P/E) ratio of -0.29, price-to-book of 1.18, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.90 and $12.23, and currently trades 92.4% below its 52-week high.

On profitability, TPST generates a return on equity (ROE) of -371.43%, return on capital employed of -385.71%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides